The IRMA Community
Newsletters
Research IRM
Click a keyword to search titles using our InfoSci-OnDemand powered search:
|
CNS Targeted Nanoparticle Drug Delivery: CNS Drug Delivery
Abstract
The idea of formulating brain permeable nanoparticles stems from the need to treat various neurological disorders like Parkinson's disease, Alzheimer's disease, schizophrenia, depression and brain tumors. Neuropeptides, antibiotics, anticancer drugs and many CNS active drugs cannot cross blood brain barrier (BBB). Studies have revealed that when these drugs are loaded on to nanoparticles they not only cross BBB, but also exhibit decreased side effects. The drug can be dissolved, dispersed, encapsulated inside the nanoparticle or attached on to surface of nanoparticles. In 1995, dalargin was the first drug to be delivered across blood brain barrier (BBB) using polysorbate 80 coated nanoparticles. The size of nanoparticles is usually between 10-1000nm. For crossing BBB it should be less than 300 nm.
Related Content
|
Wassim Jaber.
© 2024.
24 pages.
|
|
Hussein A.H. Jaber, Zahraa Saleh, Wassim Jaber, Adnan Badran, Hatem Nasser.
© 2024.
17 pages.
|
|
Sakshi Garg, Kunal Arora, Sumita Singh, K. Nagarajan.
© 2024.
20 pages.
|
|
Wassim Jaber.
© 2024.
14 pages.
|
|
Ray Gutierrez Jr..
© 2024.
22 pages.
|
|
Wassim Jaber, Hussein A.H. Jaber, Ramzi Jaber, Zahraa Saleh.
© 2024.
16 pages.
|
|
Zahraa Saleh, Wassim Jaber, Ali Jaber, Edmond Cheble, Mikhael Bechelany, Akram Hijazi, David Cornu, Ghassan Mahmoud Ibrahim.
© 2024.
22 pages.
|
|
|